SUMMARY Tests for antikeratin antibodies (AKA) were performed on 2152 disease-associated and control sera by indirect immunofluorescence (IF) on rat oesophagus substrate. The incidence of AKA was significantly raised in rheumatoid arthritis (37%) in comparison with systemic sclerosis (8%), psoriasis (7%), ankylosing spondylitis (6%), systemic lupus erythematosus (3%), and normal controls (2%). AKA were detected in synovial fluid obtained from patients with rheumatoid arthritis (RA) (48%) but not from patients with other conditions. Further experiments on AKA-positive sera showed reactivity with stratum corneum of rabbit prepuce and lips. A specific rabbit antihuman keratin antiserum was shown, by IF and inhibition studies, to have a different specificity from that of spontaneous human AKA.
It has been suggested that defective immunoregulation may be central to the pathogenesis of rheumatoid arthritis. 1 2Several non-organ-specific autoantibodies have been described in RA and in other related connective tissue diseases.3 Certain autoantibodies may be more specific for RA,4 and we have previously described a possible relationship between rheumatoid factors and autoantibodies to keratin.5 Antikeratin antibodies were first described in RA6 but have since been reported in systemic lupus erythematosus (SLE),7 systemic sclerosis 6 8 9 and ankylosing spondylitis.9
In this study we have tested for any possible disease specificity of AKA, within a spectrum of connective tissue diseases and miscellaneous conditions reported to be associated with rheumatoid factor or AKA production. We 
Results
Antikeratin antibodies of IgG class were frequently detected in RA sera (37.1%) and synovial fluid (48-3%) but only in 1/21 samples of RA saliva. Both normal and disease control groups showed a low incidence of AKA in serum (2.4-7-7%), and no positives were found in control SF or saliva samples (Table 1) . Sera from another 12 diseases associated with spontaneous production of RF also showed a low incidence of AKA.
The titre of AKA in RA sera was significantly greater than disease controls (p<0-05) and normals (p<0-04) (Fig. 1) . In a comparison of 58 paired samples of RA serum and SF (Fig. 2) used to define the specificity of naturally occurring human AKA, we found it did not block human AKA activity and instead showed binding to the basal cell layer (Fig. 3a) in contrast with the human sera which found more superficial layers of keratin in the rat oesophagus preparation (Fig. 3b) .
Discussion
In this extensive long-term study we have found serum AKA to be relatively specific for RA. Although it is of low sensitivity at a prevalence of 37% in RA, we detected AKA in only 3-8% of other connective tissue diseases. This appears to be lower than some previous reports of AKA in Sjogren's syndrome, 50%;8 AS, 25%;9 and SLE, 18%. 7 We included other RF-positive syndromes as disease controls, which also showed a low incidence of AKA, supporting the earlier demonstration that AKA do not have RF activity. (Table 3) .
High titres of AKA were mainly restricted to RA patients and we propose that a titre of 1:40 or higher may be helpful in the diagnosis of RA (Fig. 1) 10 Antibodies to rabbit stratum corneum have not previously been described in association with AKA positivity, but further analysis of AKA specificity on a rat substrate showed restriction of (spontaneous) AKA binding (in RA sera) to the more superficial layers, whereas a specific rabbit antihuman keratin antiserum bound only to the basal cell layer (Figs 3a  and b) . These two patterns of binding may represent differences in epitopic specificity between the two types of antibody tested, and further studies are in progress.
In conclusion we have found antikeratin antibodies in titres of 1/40 or above to be relatively specific for rheumatoid arthritis in a study of serum and synovial fluid. The significance and the epitopic specificity of these antibodies require further elucidation. 
